Neurophysiological Predictors of Long Term Response to AChE Inhibitors in AD Patients

Overview

Journal J Neurol Neurosurg Psychiatry

Publisher BMJ Publishing Group

Specialties Neurology
Neurosurgery
Psychiatry

Date 2005 Jul 19

PMID 16024879

Citations 63

Authors

V Di Lazzaro

A Oliviero

F Pilato

E Saturno

M Dileone

C Marra

S Ghirlanda

F Ranieri

G Gainotti

P Tonali

Affiliations

Soon will be listed here.

Abstract

Background: In vivo evaluation of cholinergic circuits of the human brain has recently been introduced using a transcranial magnetic stimulation (TMS) protocol based on coupling peripheral nerve stimulation with motor cortex TMS (short latency afferent inhibition, SAI). SAI is reduced in Alzheimer's disease (AD) and drugs enhancing cholinergic transmission increase SAI.

Methods: We evaluated whether SAI testing, together with SAI test-retest, after a single dose of the acetylcholinesterase (AChE) inhibitor rivastigmine, might be useful in predicting the response after 1 year treatment with rivastigmine in 16 AD patients.

Results: Fourteen AD patients had pathologically reduced SAI. SAI was increased after administration of a single oral dose of rivastigmine in AD patients with abnormal baseline SAI, but individual responses to rivastigmine varied widely, with SAI change ranging from an increase in inhibition of approximately 50% of test size to no change. Baseline SAI and the increase in SAI after a single dose of rivastigmine were correlated with response to long term treatment. A normal SAI in baseline conditions, or an abnormal SAI in baseline conditions that was not greatly increased by a single oral dose of rivastigmine, were invariably associated with poor response to long term treatment, while an abnormal SAI in baseline conditions in conjunction with a large increase in SAI after a single dose of rivastigmine was associated with good response to long term treatment in most of the patients.

Conclusions: Evaluation of SAI may be useful for identifying AD patients likely to respond to treatment with AChE inhibitors.

Citing Articles

TMS-derived short afferent inhibition discriminates cognitive status in older adults without dementia.

Sundman M, Green J, Fuglevand A, Chou Y Aging Brain. 2024; 6:100123.

PMID: 39132326 PMC: 11315225. DOI: 10.1016/j.nbas.2024.100123.

The effects of verbal and spatial working memory on short- and long-latency sensorimotor circuits in the motor cortex.

Lenizky M, Meehan S PLoS One. 2024; 19(5):e0302989.

PMID: 38753604 PMC: 11098330. DOI: 10.1371/journal.pone.0302989.

Clinical diagnostic utility of transcranial magnetic stimulation in neurological disorders. Updated report of an IFCN committee.

Vucic S, Stanley Chen K, Kiernan M, Hallett M, Benninger D, Di Lazzaro V Clin Neurophysiol. 2023; 150:131-175.

PMID: 37068329 PMC: 10192339. DOI: 10.1016/j.clinph.2023.03.010.

Sex differences in mild vascular cognitive impairment: A multimodal transcranial magnetic stimulation study.

Cantone M, Fisicaro F, Ferri R, Bella R, Pennisi G, Lanza G PLoS One. 2023; 18(3):e0282751.

PMID: 36867595 PMC: 9983846. DOI: 10.1371/journal.pone.0282751.

A comprehensive review of transcranial magnetic stimulation in secondary dementia.

Lanza G, Fisicaro F, Dubbioso R, Ranieri F, Chistyakov A, Cantone M Front Aging Neurosci. 2022; 14:995000.

PMID: 36225892 PMC: 9549917. DOI: 10.3389/fnagi.2022.995000.

References

OLDFIELD R . The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia. 1971; 9(1):97-113. DOI: 10.1016/0028-3932(71)90067-4. View

Di Lazzaro V, Oliviero A, Pilato F, Saturno E, Dileone M, Marra C . Motor cortex hyperexcitability to transcranial magnetic stimulation in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004; 75(4):555-9. PMC: 1739006. DOI: 10.1136/jnnp.2003.018127. View

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E . Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34(7):939-44. DOI: 10.1212/wnl.34.7.939. View

Reisberg B, Ferris S, de Leon M, Crook T . Global Deterioration Scale (GDS). Psychopharmacol Bull. 1988; 24(4):661-3. View

Villa G, Gainotti G, De Bonis C, Marra C . Double dissociation between temporal and spatial pattern processing in patients with frontal and parietal damage. Cortex. 1990; 26(3):399-407. DOI: 10.1016/s0010-9452(13)80089-5. View

Alhainen K, Riekkinen Sr P . Discrimination of Alzheimer patients responding to cholinesterase inhibitor therapy. Acta Neurol Scand Suppl. 1993; 149:16-21. DOI: 10.1111/j.1600-0404.1993.tb04248.x. View

Aarsland D, Larsen J, Reinvang I, Aasland A . Effects of cholinergic blockade on language in healthy young women. Implications for the cholinergic hypothesis in dementia of the Alzheimer type. Brain. 1994; 117 ( Pt 6):1377-84. DOI: 10.1093/brain/117.6.1377. View

Ziemann U, LONNECKER S, Steinhoff B, Paulus W . Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study. Ann Neurol. 1996; 40(3):367-78. DOI: 10.1002/ana.410400306. View

Everitt B, Robbins T . Central cholinergic systems and cognition. Annu Rev Psychol. 1997; 48:649-84. DOI: 10.1146/annurev.psych.48.1.649. View

10.

Francis P, Palmer A, Snape M, Wilcock G . The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999; 66(2):137-47. PMC: 1736202. DOI: 10.1136/jnnp.66.2.137. View

11.

Krall W, Sramek J, Cutler N . Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease. Ann Pharmacother. 1999; 33(4):441-50. DOI: 10.1345/aph.18211. View

12.

Kennedy J, Polinsky R, Johnson B, Loosen P, Enz A, Laplanche R . Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. J Clin Psychopharmacol. 1999; 19(6):513-21. DOI: 10.1097/00004714-199912000-00005. View

13.

Tokimura H, Di Lazzaro V, Tokimura Y, Oliviero A, Profice P, Insola A . Short latency inhibition of human hand motor cortex by somatosensory input from the hand. J Physiol. 2000; 523 Pt 2:503-13. PMC: 2269813. DOI: 10.1111/j.1469-7793.2000.t01-1-00503.x. View

14.

Di Lazzaro V, Oliviero A, Meglio M, Cioni B, Tamburrini G, Tonali P . Direct demonstration of the effect of lorazepam on the excitability of the human motor cortex. Clin Neurophysiol. 2000; 111(5):794-9. DOI: 10.1016/s1388-2457(99)00314-4. View

15.

Di Lazzaro V, Oliviero A, Profice P, Pennisi M, Di Giovanni S, Zito G . Muscarinic receptor blockade has differential effects on the excitability of intracortical circuits in the human motor cortex. Exp Brain Res. 2001; 135(4):455-61. DOI: 10.1007/s002210000543. View

16.

Doody R, Stevens J, Beck C, Dubinsky R, Kaye J, Gwyther L . Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001; 56(9):1154-66. DOI: 10.1212/wnl.56.9.1154. View

17.

Di Lazzaro V, Oliviero A, Tonali P, Marra C, Daniele A, Profice P . Noninvasive in vivo assessment of cholinergic cortical circuits in AD using transcranial magnetic stimulation. Neurology. 2002; 59(3):392-7. DOI: 10.1212/wnl.59.3.392. View

18.

Sailer A, Molnar G, Paradiso G, Gunraj C, Lang A, Chen R . Short and long latency afferent inhibition in Parkinson's disease. Brain. 2003; 126(Pt 8):1883-94. DOI: 10.1093/brain/awg183. View

19.

Adler G, Brassen S, Chwalek K, Dieter B, Teufel M . Prediction of treatment response to rivastigmine in Alzheimer's dementia. J Neurol Neurosurg Psychiatry. 2004; 75(2):292-4. PMC: 1738912. View

20.

Bartus R . Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: effects of concurrent administration of physostigmine and methylphenidate with scopolamine. Pharmacol Biochem Behav. 1978; 9(6):833-6. DOI: 10.1016/0091-3057(78)90364-7. View